Shoulder Innovations, Inc. (SI) company profile
Close on Nov 17, 2026Market cap $428.04MP/E –Yield –
About Shoulder Innovations
Surgical & Medical Instruments & Apparatus, SIC 3841
The company develops and commercializes medical technology solutions focused on shoulder surgical care. Its offerings center on advanced implant systems for anatomic and reverse total shoulder arthroplasty, featuring proprietary glenoid and humeral stem technologies designed to improve stability and joint biomechanics. Complementing its implants, the company provides AI- and machine-learning-driven preoperative planning software that converts medical scans into 3D patient models, alongside a streamlined two-tray surgical instrumentation system. It serves orthopedic surgeons, hospitals, and outpatient surgery centers, supported by specialized clinical personnel and independent distributors.
The business operates commercially within the United States, targeting high-volume orthopedic surgeons across inpatient facilities and ambulatory surgery centers. Its implant portfolio has been utilized in more than 17,500 surgical procedures. Commercial and clinical operations are supported by a field team of 45 shoulder specialists collaborating with a third-party distributor network. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Shoulder Innovations's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Shoulder Innovations, Inc.
- Headquarters
- Grand Rapids, MI
- Address
- 1535 Steele Avenue Sw, Suite B 49507
- Phone
- (616) 294-1026
- Website
- shoulderinnovations.com
- Employees
- 75, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Grand Rapids, Michigan
Stock & identifiers
- Ticker
- SI
- Exchange
- NYSE
- IPO date
- Aug 1, 2025
- Shares outstanding
- 21M, Jul 30, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1699350
- CUSIP
- 82537J108
- ISIN
- US82537J1088
- FIGI
- BBG00FM5V7M6
- Share class FIGI
- BBG00FM5V7N5
- LEI
- 529900LTH37ALD2K7437
- EIN
- 27-0538764
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Joseph Ball | CEO & Executive Chairman, Director | 417,942 |
| Matthew Fraser Ahearn | Chief Operating Officer, Director | 245,776 |
| Jonathan E. Osborne | Chief Commercial Officer | 60,355 |
| Jeffrey S. Points | Chief Financial Officer | 68,835 |
| David Lawrence Blue | See Remarks | 139,372 |
| Kevin K. Sidow | Director | 25,948 |
| Casey M. Tansey | Director | 2,746,564 |
| Paul Buckman | Director | 65,025 |
| Andrew Hykes | Director | 7,438 |
| Richard Buchholz | Director | 18,712 |
| Michael A. Carusi | Director | 1,626,136 |
| Geoffrey B. Pardo | Director | 2,288,148 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Robert Ball Chief Executive Officer | $467.94K | – | $494.13K | $224.61K | $15.80K | $1.20M | +91% |
| Jeffrey Points Chief Financial Officer | $378.14K | $50.00K | $98.83K | $181.51K | $11.34K | $719.82K | +42% |
| David L. Blue Chief Customer Experience Officer | $364.46K | – | $148.24K | $247.10K | $18.98K | $778.77K | +57% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 1, 2025
- Offer price
- $15.00
- Securities offered
- 5,000,000
- Gross proceeds
- $75.00M
- Exchange
- NYSE
- Lock-up ends (est.)
- Jan 28, 2026
“Per Share Total Initial public offering price $15.00 $75,000,000 Underwriting discounts and commissions (1) $1.05 $5,250,000 Proceeds, before expenses, to us $13.95 $69,750,000 __________________ (1) See the section titled “ Underwriting ” for additional disclosure regarding the estimated underwriting discounts and”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 1, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 30, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?